Medicare Part D coverage · 1 · RxCUI 1654955
1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp]
Per the CMS 2026 Part D formulary file, 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] is covered by 1,358 Medicare Part D plans (26.9% of enrollable products), averaging Tier 4.2, with prior authorization required on 96.5% of covering formularies.
- 26.9%
- Plan coverage
- 1,358
- Plans covering
- T4.2
- Avg tier
- 96.5%
- Prior auth required
What the CMS Formulary Data Shows for 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp]
Per the CMS 2026 Part D formulary file, 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] (RxNorm concept RXCUI 1654955, generic name 1) appears on 57 distinct formulary files spanning 1,358 Medicare Part D plan offerings - 26.9% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.2.
Real-world access to 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] depends on utilization management as much as tier placement: 96.5% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 5,574 Part D beneficiaries filled 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] in 2023, with total plan-and-beneficiary spending of $59,909,953 and an average per-beneficiary annual cost of $10,748.11. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] today.
Coverage Details
- Formularies covering
- 57
- Plans covering
- 1,358
- Coverage rate
- 26.9%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 96.5% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 5,574
- Total spending
- $59,909,953
- Avg per beneficiary
- $10,748.11
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Gold Coast Health Plan Total Care Advantage (HMO D-SNP) | Ventura County Medi-Cal Managed Care Commission | T1 | Yes | $0 | CA |
| Blue Cross Medicare Advantage Dual Care Plus (HMO D-SNP) | Health Care Service Corporation | T1 | Yes | $0 | NM |
| Blue Cross MA Dual Care Plus Preferred (PPO D-SNP) | Health Care Service Corporation | T1 | Yes | $0 | NM |
| SecureBlue (HMO D-SNP) | HMO Minnesota | T1 | Yes | $0 | MN |
| Hamaspik Medicare Choice (HMO D-SNP) | Hamaspik, Inc. | T1 | Yes | $0 | NY |
| SeniorCare Complete (HMO D-SNP) | South Country Health Alliance | T1 | Yes | $0 | MN |
| AbilityCare (HMO D-SNP) | South Country Health Alliance | T1 | Yes | $0 | MN |
| Alameda Alliance Wellness (HMO D-SNP) | Alameda Alliance FOR Health | T1 | Yes | $0 | CA |
| Community Care's Partnership Program (HMO D-SNP) | Community Care Health Plan, Inc. | T1 | Yes | $0 | WI |
| Platino Blindao (HMO D-SNP) | Triple S Advantage, Inc. | T1 | Yes | $0 | PR |
| Platino Enlace (HMO D-SNP) | Triple S Advantage, Inc. | T1 | Yes | $0 | PR |
| Platino Advance (HMO D-snp) | Triple S Advantage, Inc. | T1 | Yes | $0 | PR |
| Platino Plus (HMO D-snp) | Triple S Advantage, Inc. | T1 | Yes | $0 | PR |
| Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) | Gateway Health Plan, Inc. | T1 | Yes | $0 | PA |
| Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) | Gateway Health Plan, Inc. | T1 | Yes | $0 | PA |
| Highmark Health Options Duals (HMO D-SNP) | Highmark Health Options West Virginia Inc. | T1 | Yes | $0 | WV |
| Highmark Health Options Duals (HMO D-SNP) | Highmark Bcbsd, Inc. | T1 | Yes | $0 | DE |
| Blue Cross Medicare Advantage Dual Care Plus (HMO D-SNP) | Hcsc Insurance Services Company | T1 | Yes | $4.80 | TX |
| Blue Cross Medicare Advantage Dual Care Plus (HMO D-SNP) | GHS Insurance Company | T1 | Yes | $5.00 | OK |
| Highmark Wholecare Medicare Assured Ruby (HMO D-SNP) | Gateway Health Plan, Inc. | T1 | Yes | $13.10 | PA |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] covered by Medicare Part D?
Yes, 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] is covered by 1,358 Medicare Part D plans (26.9% of all Part D formularies).
What tier is 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] on Medicare Part D plans?
1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] averages Tier 4.2 across Part D plans, ranging from Tier 1 to Tier 5.
Does 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] require prior authorization?
96.5% of Part D formularies require prior authorization for 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp]?
In 2023, total Medicare Part D spending on 1 ML darbepoetin alfa 0.2 MG/ML Injection [Aranesp] was $59,909,953, covering 5,574 beneficiaries. The average spend per beneficiary was $10,748.11.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- everolimus 10 MG Oral Tablet T4.2
- {56 (elexacaftor 50 MG / ivacaftor 37.5 MG / tezacaftor 25 MG Oral Tablet) / 28 (ivacaftor 75 MG Oral Tablet) } Pack [Trikafta (50 MG / 37.5 MG / 25 MG; 75 MG)] T4.2
- 1.5 ML leuprolide acetate 7.5 MG/ML Prefilled Syringe [Lupron] T4.2
- alpha 1-proteinase inhibitor, human 1 MG Injection [Prolastin] T4.2
- ivacaftor 150 MG Oral Tablet [Kalydeco] T4.2
- tenofovir alafenamide 25 MG Oral Tablet [Vemlidy] T4.2
Similar prior-authorization rate
- armodafinil 250 MG Oral Tablet 96.5% PA
- armodafinil 150 MG Oral Tablet 96.5% PA
- 0.5 ML ustekinumab-aekn 90 MG/ML Prefilled Syringe [Selarsdi] 96.6% PA
- 10 ML acyclovir 50 MG/ML Injection 96.6% PA
- tretinoin 0.5 MG/ML Topical Lotion [Altreno] 96.6% PA
- amifampridine 10 MG Oral Tablet [Firdapse] 96.4% PA